Journal of Clinical Pediatrics >
Clinical phenotypes and gene mutations analysis of children with STXBP1 gene-related encephalopathy
Received date: 2022-08-22
Online published: 2024-02-02
Objective To investigate the clinical phenotype and genetic characteristics of children with developmental and epileptic encephalopathy(DEE) caused by syntaxin-binding protein 1(STXBP1) gene mutation. Methods The clinical data of 11 patient with STXBP1 gene-related encephalopathy admitted to the Third Affiliated Hospital of Zhengzhou University from October 2015 to May 2022 were retrospectively reviewed, and their clinical phenotypes, gene outcomes, treatment and efficacy were analyzed. Results Of the 11 children, 4 were males and 7 were females, 10 had seizures with developmental delay and 1 showed only developmental delay. The age of onset of epilepsy was 3 days to 1.5 years, with 6 cases starting at less than 3 months, 3 at 3-12 months, and 1 at more than 1 year of age. The common seizure types are epileptic spasm and focal seizure. All the 11 patients had the abnormal interictal electroencephalograms (EEG) including background slowness, multifocal discharge, suppression-burst, and hypsarrhythmia. Two cases had Otahara syndrome in the early stages, which evolved into infantile spasms in the later stages, five cases had infantile spasms, and the rest had epileptic syndromes that could not be typed. Four children had non-specific abnormalities on cranial MRI, including poor development of myelination, and widening of the subarachnoid space in the frontotemporal region.frontotemporal. All children had STXBP1 gene variants, with a total of 11 variant types, including 7 missense variants, 1 frameshift variant, 1 splicing variant, and 2 deletion variants, and the variant loci of the 7 children have not been reported in the literature, which were c.1694T>A, c.1115T>G, C.133_135del, C.1543dupG, exons 6-17 heterozygous deletion, C.429+1G>C, C.855C>G and c.842_843insGGACGACGGCCTGTGGGATAGCACT. During follow-up, 11patients had different degrees of developmental delay, 2 patients had died, and 4 patients had autistic like features. Ten patients with epilepsy were treated with levetiracetam. One patient was seizure free with levetiracetam alone, 5 patients showed partial response, and 4 patients showed no response on multitherapy. 3 patients was seizure free, the remaining 7 patients were drug resistant epilepsy. Conclusion STXBP1 gene-related epilepsy usually occur to infant, and infantile spasm is the most common phenotype. There is significant heterogeneity in the therapeutic effect of epilepsy. Seven unreported mutation sites enriched the gene spectrum of STXBP1 encephalopathy.
Xiaoli LI , Xiaoli ZHANG , Xiao LI , Rui HAN , Dan XU , Ling GAN , Tianming JIA . Clinical phenotypes and gene mutations analysis of children with STXBP1 gene-related encephalopathy[J]. Journal of Clinical Pediatrics, 2024 , 42(2) : 127 -132 . DOI: 10.12372/jcp.2024.22e1145
| [1] | Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology[J]. Epilepsia, 2017, 58(4): 512-521. |
| [2] | Howell KB, Eggers S, Dalziel K, et al. A population based cost-effectiveness study of early genetic testing in severe epilepsies of infancy[J]. Epilepsia, 2018, 59(6): 1177-1187. |
| [3] | Shu T, Jin H, Rothman JE, et al. Munc13-1 MUN domain and Munc18-1 cooperatively chaperone SNARE assembly through a tetrameric complex[J]. Proc Natl Acad Sci U S A, 2020, 17(2): 1036-1041. |
| [4] | Saitsu H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy[J]. Nat Genet, 2008, 40(6): 782-788. |
| [5] | Hamdan FF, Srour M, Capo-Chichi JM, et al. De novo mutations in moderate or severe intellectual disability[J]. PLoS Genet, 2014, 10(10): e1004772. |
| [6] | Romaniello R, Saettini F, Panzeri E, et al. A De-novo STXBP1 gene mutation in a patient showing the Rett syndrome phenotype[J]. Neuroreport, 2015, 26(5): 254-257. |
| [7] | Stamberger H, Nikanorova M, Willemsen MH, et al. STXBP encephalopathy: A neurodevelopmental disorder including epilepsy[J]. Neurology, 2016, 86(10): 954-962. |
| [8] | Takeda K, Miyamoto Y, Yamamoto H, et al. Mutation in the STXBP1 gene associated with early onset west syndrome: a case report and literature review[J]. Pediatr Rep, 2022, 14(4): 386-395. |
| [9] | 曹佳捷, 姬辛娜, 毛莹莹, 等. STXBP1脑病患儿临床特征及遗传学特点[J]. 中华儿科杂志, 2020, 58(6): 493-498. |
| [10] | 辛文佳, 贺进波. 传统和新型抗癫痫药物治疗新诊断癫痫患者的 1 年保留率比较[J]. 临床合理用药, 2021, 14(2): 73-75. |
| [11] | Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies[J]. Epilepsia, 2010, 51(6): 1069-1077. |
| [12] | Han J, Pluhackova K, B?ckmann RA. The multifaceted role of SNARE proteins in membrane fusion[J]. Front Physiol, 2017, 8: 5. |
| [13] | Zhu B, Mak JCH, Morris AP, et al. Functional analysis of epilepsy-associated variants in STXBP1/Munc18-1 using humanized Caenorhabditis elegans[J]. Epilepsia, 2020, 61(4): 810-821. |
| [14] | Chen W, Cai ZL, Chao ES, et al. Stxbp1/Munc18-1 haploinsufficiency impairs inhibition and mediates key neurological features of STXBP1 encephalopathy[J]. Elife, 2020, 9: e48705. |
| [15] | Otsuka M, Oguni H, Liang JS, et al. STXBP1 mutations cause not only Ohtahara syndrome but also West syndrome-result of Japanese cohort study[J]. Epilepsia, 2010, 51(12): 2449-2452. |
| [16] | Scantlebury MH, Barrett KT, Jacinto S, et al. Cou Cou, flying fish and a whole exome please... lessons learned from genetic testing in Barbados[J]. Pan Afr Med J, 2021, 38: 111. |
| [17] | Steel D, Symonds JD, Zuberi SM, et al. Dravet syndrome and its mimics: Beyond SCN1A[J]. Epilepsia, 2017, 58(11): 1807-1816. |
| [18] | Stamberger H, Nikanorova M, Willemsen MH, et al. STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy[J]. Neurology, 2016, 86(10): 954-962. |
| [19] | Xian J, Parthasarathy S, Ruggiero SM, et al. Assessing the landscape of STXBP1-related disorders in 534 individuals[J]. Brain, 2022, 145(5): 1668-1683. |
| [20] | Sivaraju A, Nussbaum I, Cardoza CS, et al. Substantial and sustained seizure reduction with ketogenic diet in a patient with Ohtahara syndrome[J]. Epilepsy Behav Case Rep, 2015, 3: 43-45. |
| [21] | Gburek-Augustat J, Beck-Woedl S, Tzschach A, et al. Epilepsy is not a mandatory feature of STXBP1 associated ataxia-Tremor-retardation syndrome[J]. Eur J Paediatr Neurol, 2016, 20(4): 661-665. |
| [22] | Abramov D, Guiberson NGL, Burré J. STXBP1 ence-phalopathies: clinical spectrum, disease mechanisms and therapeutic strategies[J]. J Neurochem, 2021, 157(2): 165-178. |
| [23] | Balagura G, Xian J, Riva A, et al. Epilepsy course and developmental trajectories in STXBP1-DEE[J]. Neurol Genet, 2022, 8(3): e676. |
| [24] | 许猛, 叶婷婷, 刘晓蓉. STXBP1基因相关疾病的研究进展[J]. 临床神经病学杂志, 2021, 43(2): 149-152. |
| [25] | Nam JY, Teng LY, Cho K, et al. Effects of the ketogenic diet therapy in patients with STXBP1-related encephalopathy[J]. Epilepsy Res, 2022, 186: 106993. |
| [26] | Wang QH, Cao JJ, Wang YY, et al. Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra[J]. Seizure, 2022, 95: 64-74. |
/
| 〈 |
|
〉 |